FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	DVAL
OMB Number:	3235-0287
Estimated average by	urden
hours per response	. 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person *				2. Issuer Name and Ticker or Trading Symbol					5. Re	5. Relationship of Reporting Person(s) to Issuer					
Mayer Eldon C. III]	RIGEL PHARMACEUTICALS INC [RIGL]						(Check all applicable) Director 10% Owner					
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 03/20/2019						X					
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)					_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqu						Acquired,	nired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			Execution Date, if Co			(A) or		f (D) Owner Trans	Transaction(s) (Instr. 3 and 4)		I (Ownership of Borm: Borect (D) O	Nature f Indirect eneficial wnership nstr. 4)		
Reminder: Ro								in this fo	who respond orm are not re tly valid OMB	quired to r	espond (74 (9-02)
								in this fo	rm are not re	quired to r	espond (74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative		3A. Deemed Execution Date, if	4. Transact	tion	ls, warra 5. Numb of Deriva Securitie Acquired or Dispo	er ative s	in this for a current ired, Dispos options, con 6. Date Exeritation I (Month/Day	orm are not re tly valid OMB ed of, or Benef vertible securit reisable and Date	quired to recontrol nu	espond umber. ed Amount	8. Price of	9. Number o Derivative Securities Beneficially Owned	f 10. Ownership Form of Derivative Security:	11. Natu of Indire Benefici
1. Title of Derivative Security	Conversion or Exercise Price of	Date	3A. Deemed Execution Date, if any	4. Transact	tion	ls, warra 5. Numb of Deriva Securitie Acquired	er ative s l (A) sed	in this for a current ired, Dispos options, con 6. Date Exeritation I (Month/Day	orm are not re tly valid OMB ed of, or Benef vertible securit reisable and Date	required to recontrol nutricially Owneries) 7. Title and of Underlying Securities	espond umber. ed Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indires Benefici Ownersk (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact	tion	ds, warra 5. Numb of Deriva Securitie Acquired or Dispo of (D) (Instr. 3,	er ative s l (A) sed	in this for a current ired, Dispos options, con 6. Date Exeritation I (Month/Day	erm are not re tly valid OMB ed of, or Benef vertible securit reisable and Date //Year)	required to recontrol nutricially Owneries) 7. Title and of Underlying Securities	espond umber. ed Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natu of Indire Benefic Owners (Instr. 4

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Mayer Eldon C. III RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			EVP & Chief Commercial Officer			

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	03/22/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On January 24, 2018, the reporting person was granted a performance based option to purchase 75,000 shares of common stock based on a specific performance metric. On March 20, (1) 2019, it was determined that the performance metric had been met.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.